Lactate Dehydrogenase (Ldh) Levels To Predict Benefit From The Continuation Of Bevacizumab (Bev) Beyond Progression In Metastatic Colorectal Cancer (Mcrc): Subgroup Analysis Of The Randomized Bebyp Study

Federica Marmorino,Chiara Cremolini,Fotios Loupakis,Cecilia Barbara,Francesco Dargenio, Emanuela Miraglio,Gianluca Masi,Lisa Salvatore,Lorenzo Marcucci,Lorenzo Antonuzzo,Silvana Chiara,Chiara Banzi,Marta Schirripa,Domenico Amoroso,Andrea Bonetti,Angelo Martignetti,Myriam Paris,Luca Boni,Daniela Tomcikova,Alfredo Falcone

ANNALS OF ONCOLOGY（2016）

引用 0|浏览39

暂无评分

摘要

e15127Background: Different antiangiogenic agents are available as 2nd line options for mCRC patients (pts). Up today, no clinical or molecular predictors of benefit have been identified. In precli...

查看译文

关键词

metastatic colorectal cancer,colorectal cancer,bevacizumab,lactate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要